Table 4 Comparison of clinicopathologic features of long-term survivors (≥60 months) and non-long-term survivors
From: Factors responsible for long-term survival in metastatic breast cancer
| Â | All patients | Patients with OS >60 months | Patients with OS <60 months | P value |
|---|---|---|---|---|
Number | 70 | 17 | 28 | Â |
Age (years) | 60 (32-82) | 60 (37-82) | 56.5 (36-81) | 0.86 |
Disease-free interval (months) | 36 (3-286) | 60 (13-241) | 13 (3-62) | 0.01 |
Number of disease sites | 2 (1-6) | 2 (1-3) | 2 (1-6) | 0.2 |
Visceral lesion (%) | 51.4 | 52.9 | 50 | 0.91 |
Tumor grade | 3 (1-3) | 2 (1-3) | 3 (1-3) | 0.07 |
Hormone-sensitive (%) | 60 | 88.2 | 28.6 | <0.00002 |
HER2-overexpressed (%) | 18.2 | 33.3 | 17.9 | 0.55 |
Triple negative (%) | 28.6 | 5.9 | 60.7 | 0 |
Prior A and T treatment (%) | 35.7 | 41.2 | 39.3 | 0.67 |
CT line | 2 (1-5) | 3 (1-5) | 2 (1-4) | 0.2 |
CT line for MBC | 1 (1-5) | 2 (1-5) | 1 (1-3) | 0.07 |
Metronomic regimen (%) | 45.7 | 64.7 | 35.7 | 0.03 |
Trastuzumab administration (%) | 21.3 | 23.5 | 16.7 | 0.41 |